Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Silence Therapeutics Plc ADR
(NQ:
SLN
)
16.20
+0.67 (+4.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Silence Therapeutics Plc ADR
< Previous
1
2
Next >
Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development
March 28, 2023
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Buyback siRNA Complement Assets
March 28, 2023
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results
March 15, 2023
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023
March 02, 2023
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Present at SVB Securities Global Biopharma Conference
February 08, 2023
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer
February 06, 2023
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
January 12, 2023
From
Silence Therapeutics
Via
Business Wire
Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Silence Therapeutics
Via
Business Wire
Silence Therapeutics Reports Third Quarter 2022 Results
November 10, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Present at Jefferies London Healthcare Conference
November 09, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting
November 05, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
September 29, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference
September 27, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Participate in September Investment Conferences
September 08, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera
September 08, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces Pricing of Underwritten Offering
August 11, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Present at Jefferies Healthcare Conference
June 02, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference
May 18, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Reports First Quarter 2022 Results
May 16, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration
April 25, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Present at 21st Annual Needham Virtual Healthcare Conference
April 06, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces Publication in the Journal of the American Medical Association Highlighting Results From SLN360 Phase 1 Study in Healthy Adults With High Lipoprotein(a)
April 03, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting
April 03, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501
March 23, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results
March 17, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer
February 21, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)
February 09, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at the American College of Cardiology (ACC) Annual Scientific Session and Expo
January 26, 2022
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics’ Head of Molecular Design Dr. Marie Wikström Lindholm Appointed to Oligonucleotide Therapeutics Society Board of Directors
January 18, 2022
From
Silence Therapeutics plc
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.